Sunni L Mumford1, Richard S Legro1, Michael P Diamond1, Christos Coutifaris1, Anne Z Steiner1, William D Schlaff1, Ruben Alvero1, Gregory M Christman1, Peter R Casson1, Hao Huang1, Nanette Santoro1, Esther Eisenberg1, Heping Zhang1, Marcelle I Cedars1. 1. Epidemiology Branch, Division of Intramural Population Health Research (S.L.M.), Eunice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, Maryland; Department of Obstetrics and Gynecology (R.S.L.), Pennsylvania State University, Hershey, Pennsylvania; Department of Obstetrics and Gynecology (M.P.D.), Augusta University, Augusta, Georgia; Department of Obstetrics and Gynecology (C.C.), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Department of Obstetrics and Gynecology (A.Z.S.), University of North Carolina, Chapel Hill, North Carolina; Department of Obstetrics and Gynecology (R.A., N.S.), University of Colorado Anschutz Medical Campus, Aurora, Colorado; Department of Obstetrics and Gynecology (G.M.C.), University of Michigan, Ann Arbor, Michigan; Department of Obstetrics and Gynecology (P.R.C.), University of Vermont, Burlington, Vermont; Department of Biostatistics (H.H., H.Z.), Yale University School of Public Health, New Haven, Connecticut; Fertility and Infertility Branch (E.E.), Eunice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, Maryland; and Department of Obstetrics, Gynecology and Reproductive Sciences (M.I.C.), University of California-San Francisco, San Francisco, California.
Abstract
CONTEXT: Anti-Müllerian hormone (AMH) reduces aromatase activity and sensitivity of follicles to FSH stimulation. Therefore, elevated serum AMH may indicate a higher threshold for response to ovulation induction in women with polycystic ovary syndrome (PCOS). OBJECTIVE: This study sought to determine the association between AMH levels and ovulatory response to treatment among the women enrolled into the Pregnancy in PCOS II (PPCOS II) trial. DESIGN AND SETTING: This was a secondary analysis of data from a randomized clinical trial in academic health centers throughout the United States Participants: A total of 748 women age 18-40 years, with PCOS and measured AMH levels at baseline, were included in this study. MAIN OUTCOME MEASURES: Couples were followed for up to five treatment cycles to determine ovulation (midluteal serum progesterone > 5 ng/mL) and the dose required to achieve ovulation. RESULTS: A lower mean AMH and AMH per follicle was observed among women who ovulated compared with women who never achieved ovulation during the study (geometric mean AMH, 5.54 vs 7.35 ng/mL; P = .0001; geometric mean AMH per follicle, 0.14 vs 0.18; P = .01) after adjustment for age, body mass index, T, and insulin level. As AMH levels increased, the dose of ovulation induction medication needed to achieve ovulation also increased. No associations were observed between antral follicle count and ovulation. CONCLUSIONS: These results suggest that high serum AMH is associated with a reduced response to ovulation induction among women with PCOS. Women with higher AMH levels may require higher doses of medication to achieve ovulation.
RCT Entities:
CONTEXT: Anti-Müllerian hormone (AMH) reduces aromatase activity and sensitivity of follicles to FSH stimulation. Therefore, elevated serum AMH may indicate a higher threshold for response to ovulation induction in women with polycystic ovary syndrome (PCOS). OBJECTIVE: This study sought to determine the association between AMH levels and ovulatory response to treatment among the women enrolled into the Pregnancy in PCOS II (PPCOS II) trial. DESIGN AND SETTING: This was a secondary analysis of data from a randomized clinical trial in academic health centers throughout the United States Participants: A total of 748 women age 18-40 years, with PCOS and measured AMH levels at baseline, were included in this study. MAIN OUTCOME MEASURES: Couples were followed for up to five treatment cycles to determine ovulation (midluteal serum progesterone > 5 ng/mL) and the dose required to achieve ovulation. RESULTS: A lower mean AMH and AMH per follicle was observed among women who ovulated compared with women who never achieved ovulation during the study (geometric mean AMH, 5.54 vs 7.35 ng/mL; P = .0001; geometric mean AMH per follicle, 0.14 vs 0.18; P = .01) after adjustment for age, body mass index, T, and insulin level. As AMH levels increased, the dose of ovulation induction medication needed to achieve ovulation also increased. No associations were observed between antral follicle count and ovulation. CONCLUSIONS: These results suggest that high serum AMH is associated with a reduced response to ovulation induction among women with PCOS. Women with higher AMH levels may require higher doses of medication to achieve ovulation.
Authors: M P Lauritsen; J G Bentzen; A Pinborg; A Loft; J L Forman; L L Thuesen; A Cohen; D M Hougaard; A Nyboe Andersen Journal: Hum Reprod Date: 2014-01-16 Impact factor: 6.918
Authors: Irene Cimino; Filippo Casoni; Xinhuai Liu; Andrea Messina; Jyoti Parkash; Soazik P Jamin; Sophie Catteau-Jonard; Francis Collier; Marc Baroncini; Didier Dewailly; Pascal Pigny; Mel Prescott; Rebecca Campbell; Allan E Herbison; Vincent Prevot; Paolo Giacobini Journal: Nat Commun Date: 2016-01-12 Impact factor: 14.919
Authors: Irene Souter; Fangbai Sun; Heping Zhang; Michael P Diamond; Richard S Legro; Robert A Wild; Karl R Hansen; Nanette Santoro Journal: Fertil Steril Date: 2022-02 Impact factor: 7.329
Authors: Samantha F Butts; David B Seifer; Nathanael Koelper; Suneeta Senapati; Mary D Sammel; Andrew N Hoofnagle; Andrea Kelly; Steven A Krawetz; Nanette Santoro; Heping Zhang; Michael P Diamond; Richard S Legro Journal: J Clin Endocrinol Metab Date: 2019-02-01 Impact factor: 5.958
Authors: J Friis Petersen; E Løkkegaard; L F Andersen; K Torp; A Egeberg; L Hedegaard; D Nysom; A Nyboe Andersen Journal: Hum Reprod Open Date: 2019-02-27
Authors: Helen Jopling; Allen Yates; Nicholas Burgoyne; Katharine Hayden; Christopher Chaloner; Lesley Tetlow Journal: Endocrinol Diabetes Metab Date: 2018-07-18